---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-008987"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2022-04-12T23:59:59+00:00"
generated_at: "2026-06-26T07:50:40.018892+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology CMO Katherine Ruffner departs; Sandra Silberman named interim senior medical advisor

## Summary
- CMO Katherine Ruffner leaving April 22, 2022; will provide transitional support.
- Separation agreement includes $75,000 cash payment, base salary, unused PTO, expense reimbursement.
- Sandra Silberman, former chief medical advisor (2017-2021), returns as senior medical advisor on interim basis.
- Silberman has experience at Pfizer, Novartis, Eisai; currently CMO at Moleculin Biotech and CNS Pharmaceuticals.
- CEO states clinical trials remain on track and on schedule.

## SEC filing metadata
- accession: 0001628280-22-008987
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2022-04-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828022008987/0001628280-22-008987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828022008987/crdf-20220407.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-008987
- JSON: https://secwatch.observer/filing/0001628280-22-008987.json
- Plain text: https://secwatch.observer/filing/0001628280-22-008987.txt

## Key facts
- Executive change
  Sandra L. Silberman, M.D., Ph.D. was appointed as senior medical advisor at Cardiff Oncology, Inc..
  - Action: appointed
  - Role: senior medical advisor
  source text: Sandra L. Silberman, M.D., Ph.D., who previously acted as a chief medical advisor to Cardiff Oncology from June 2017 to July 2021, has agreed to serve as the Company’s senior medical advisor and oversee its clinical trials and clinical operations team on an interim basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828022008987/0001628280-22-008987-index.htm
- Executive change
  Katherine Ruffner, M.D. resigned as Chief Medical Officer at Cardiff Oncology, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On April 12, 2022, Cardiff Oncology, Inc. (the “Company”) announced that Katherine Ruffner, M.D., the Company’s Chief Medical Officer, will be leaving the Company on April 22, 2022, to pursue a new opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828022008987/0001628280-22-008987-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.